Table 2.
Patients initiating adjuvant endocrine therapy among all women diagnosed with breast cancer by therapy type, 2007–2009
| Patients (%) receiving AET by type (any, tamoxifen, or aromatase inhibitors) | ||||
|---|---|---|---|---|
|
| ||||
| AJCC Tumor stage I–III | ||||
|
| ||||
| Total cohort | ER+ or PR+ | ER− and PR− | ER/PR unknown | |
|
| ||||
| n=14,902 | n=12,184 | n=1,986 | n=732 | |
| Initiation of any AET | ||||
|
| ||||
| Total Cohort | 64.5 | 74.8 | 5.6 | 54.0 |
| Race/Ethnicity | ||||
| Non-Hispanic White | 65.0 | 74.4 | 5.3 | 54.5 |
| Non-Hispanic Black | 57.2 | 73.1 | 6.4 | 50.7 |
| Hispanic | 67.0 | 79.2 | 7.6 | 63.5 |
| Asian | 65.4 | 77.5 | 5.9 | 39.5 |
| Age (years) | ||||
| 65–69 | 69.5 | 81.1 | 6.0 | 61.2 |
| 70–74 | 69.7 | 81.1 | 6.2 | 57.6 |
| 75–79 | 65.1 | 74.5 | 5.9 | 58.7 |
| ≥80 | 55.4 | 64.0 | 4.6 | 45.2 |
| SES (% living below FPL) | ||||
| 1st tertile (<5.4) | 64.9 | 75.1 | 3.8 | 49.7 |
| 2nd tertile (5.4–11.8) | 64.5 | 73.7 | 6.0 | 55.9 |
| 3rd tertile (>11.8) | 64.1 | 75.6 | 6.9 | 54.8 |
| Comorbidity scores | ||||
| 0 | 66.5 | 76.4 | 5.8 | 59.6 |
| 1 | 63.6 | 74.5 | 4.5 | 48.5 |
| 2 | 61.3 | 70.6 | 6.1 | 53.1 |
| 3+ | 58.6 | 69.7 | 7.3 | 45.4 |
|
| ||||
| Initiation of tamoxifen | ||||
|
| ||||
| Total Cohort | 17.6 | 12.9 | 2.1 | 10.7 |
| Race/Ethnicity | ||||
| Non-Hispanic White | 12.0 | 13.6 | 2.1 | 10.9 |
| Non-Hispanic Black | 8.0 | 9.5 | <5% | <16% |
| Hispanic | 8.6 | 9.8 | <8% | <17% |
| Asian | 9.5 | 10.8 | <11% | <29% |
| Age (years) | ||||
| 65–69 | 10.4 | 11.8 | 2.8 | 8.8 |
| 70–74 | 11.2 | 12.8 | <3% | <13% |
| 75–79 | 11.3 | 12.9 | <3% | <9% |
| ≥80 | 12.5 | 14.2 | 2.0 | 11.9 |
| SES (% living below FPL) | ||||
| 1st tertile (<5.4) | 9.6 | 11.0 | <2% | <9% |
| 2nd tertile (5.4–11.8) | 11.8 | 13.5 | <3% | <8% |
| 3rd tertile (>11.8) | 12.6 | 14.4 | 2.7 | 13.0 |
| Comorbidity scores | ||||
| 0 | 12.1 | 13.6 | 2.4 | 13.2 |
| 1 | 11.0 | 12.7 | <3% | <10% |
| 2 | 10.2 | 11.5 | <6% | <12% |
| 3+ | 9.7 | 11.5 | <6% | <13% |
|
| ||||
| Initiation of aromatase inhibitors | ||||
|
| ||||
| Total Cohort | 53.2 | 61.8 | 3.5 | 43.4 |
| Race/Ethnicity | ||||
| Non-Hispanic White | 53.0 | 60.9 | 3.3 | 43.6 |
| Non-Hispanic Black | 49.2 | 63.6 | <5% | <40% |
| Hispanic | 58.4 | 69.4 | <8% | <56% |
| Asian | 55.9 | 66.7 | <11% | <29% |
| Age (years) | ||||
| 65–69 | 59.1 | 69.3 | 3.2 | 52.4 |
| 70–74 | 58.5 | 68.3 | 4.6 | 45.0 |
| 75–79 | 53.8 | 61.6 | 4.1 | 50.4 |
| ≥80 | 42.9 | 49.8 | 2.6 | 33.2 |
| SES (% living below FPL) | ||||
| 1st tertile (<5.4) | 55.3 | 64.1 | 2.7 | 41.3 |
| 2nd tertile (5.4–11.8) | 52.6 | 60.2 | 3.6 | 47.9 |
| 3rd tertile (>11.8) | 51.7 | 61.2 | 4.2 | 41.8 |
| Comorbidity scores | ||||
| 0 | 54.4 | 62.9 | 3.4 | 46.4 |
| 1 | 52.7 | 61.8 | 3.2 | 39.2 |
| 2 | 51.1 | 59.1 | <6% | <44% |
| 3+ | 48.9 | 58.3 | <6% | <41% |
AET, adjuvant endocrine therapy; ER, estrogen receptor; PR, progesterone receptor.